- Report
- March 2026
- 320 Pages
Global
From €3741EUR$4,150USD£3,214GBP
- Report
- September 2026
- 196 Pages
Global
From €3196EUR$3,545USD£2,746GBP
€3551EUR$3,939USD£3,051GBP
- Report
- September 2026
- 195 Pages
Global
From €3196EUR$3,545USD£2,746GBP
€3551EUR$3,939USD£3,051GBP
- Report
- February 2026
- 250 Pages
Global
From €4047EUR$4,490USD£3,477GBP
- Report
- September 2026
- 384 Pages
Global
From €5273EUR$5,850USD£4,531GBP
- Report
- February 2026
- 250 Pages
Global
From €4047EUR$4,490USD£3,477GBP
- Report
- May 2026
- 250 Pages
Global
From €4047EUR$4,490USD£3,477GBP
- Report
- April 2026
- 250 Pages
Global
From €4047EUR$4,490USD£3,477GBP
- Report
- February 2026
- 250 Pages
Global
From €4047EUR$4,490USD£3,477GBP
- Report
- February 2026
- 250 Pages
Global
From €4047EUR$4,490USD£3,477GBP
- Report
- February 2026
- 250 Pages
Global
From €4047EUR$4,490USD£3,477GBP
- Report
- September 2026
- 192 Pages
Global
From €3196EUR$3,545USD£2,746GBP
€3551EUR$3,939USD£3,051GBP
- Report
- May 2026
- 180 Pages
Global
From €4056EUR$4,500USD£3,485GBP
- Report
- July 2026
- 200 Pages
Global
From €7202EUR$7,990USD£6,188GBP
- Drug Pipelines
- March 2026
- 150 Pages
Global
From €3380EUR$3,750USD£2,904GBP
- Report
- January 2026
- 250 Pages
Global
From €3155EUR$3,500USD£2,711GBP
- Report
- November 2025
- 200 Pages
Global
From €7166EUR$7,950USD£6,157GBP
- Report
- January 2026
- 500 Pages
Global
From €4507EUR$5,000USD£3,872GBP
- Report
- July 2026
- 120 Pages
Global
From €4282EUR$4,750USD£3,679GBP
- Report
- October 2025
- 160 Pages
Global
From €2849EUR$3,160USD£2,447GBP
€3561EUR$3,950USD£3,059GBP

The Tumor Antigen market is a subset of the Oncology Drugs market, which focuses on the development of drugs to treat cancer. Tumor antigens are molecules that are expressed on the surface of cancer cells and can be recognized by the immune system. These antigens can be used to develop drugs that target and destroy cancer cells, while leaving healthy cells unharmed. Tumor antigens can be used to develop vaccines, monoclonal antibodies, and other immunotherapies. These therapies can be used to treat a variety of cancers, including breast, lung, and colorectal cancer.
Some companies in the Tumor Antigen market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Roche. These companies are actively researching and developing new treatments for cancer, including immunotherapies that target tumor antigens. Show Less Read more